KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Raw Materials (2016 - 2025)

Historic Raw Materials for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q1 2025 value amounting to $640000.0.

  • Ionis Pharmaceuticals' Raw Materials fell 9733.58% to $640000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $640000.0, marking a year-over-year decrease of 9733.58%. This contributed to the annual value of $5.6 million for FY2024, which is 20701.66% up from last year.
  • As of Q1 2025, Ionis Pharmaceuticals' Raw Materials stood at $640000.0, which was down 9733.58% from $5.6 million recorded in Q4 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Raw Materials peaked at $24.6 million during Q2 2024, and registered a low of $640000.0 during Q1 2025.
  • Moreover, its 5-year median value for Raw Materials was $18.6 million (2021), whereas its average is $17.0 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Raw Materials soared by 20701.66% in 2024, and later tumbled by 9733.58% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Raw Materials stood at $18.6 million in 2021, then rose by 5.97% to $19.8 million in 2022, then crashed by 90.84% to $1.8 million in 2023, then skyrocketed by 207.02% to $5.6 million in 2024, then tumbled by 88.48% to $640000.0 in 2025.
  • Its Raw Materials stands at $640000.0 for Q1 2025, versus $5.6 million for Q4 2024 and $21.7 million for Q3 2024.